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Abstract Observational healthcare databases represent a valuable resource for health
economics, outcomes research, quality of care, drug safety, epidemiology and comparative
effectiveness research. The methods used to identify a population for study in an obser-
vational healthcare database with the desired drug exposures of interest are complex and
not consistent nor apparent in the published literature. Our research evaluates three drug
classification systems and their impact on prevalence in the analysis of observational
healthcare databases using opioids as a case in point. The standard terminologies compiled
in the Observational Medical Outcomes Partnership’s Common Data Model vocabulary
were used to facilitate the identification of populations with opioid exposures. This study
analyzed three distinct observational healthcare databases and identified patients with at
least one exposure to an opioid as defined by drug codes derived through the application of
three classification systems. Opioid code sets were created for each of the three classifi-
cation systems and the number of identified codes was summarized. We estimated the
prevalence of opioid exposure in three observational healthcare databases using the three
defined code sets. In addition we compared the number of drug codes and distinct ingre-
dients that were identified using these classification systems. We found substantial vari-
ation in the prevalence of opioid exposure identified using an individual classification
system versus a composite method using multiple classification systems. To ensure
transparent and reproducible research publications should include a description of the
process used to develop code sets and the complete code set used in studies.
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Opioids are strong analgesics which are increasingly used for the treatment of chronic
malignant and nonmalignant pain (Ballantyne and Mao 2003; Sullivan et al. 2008). Sys-
tematic reviews of randomized controlled trials have confirmed their short-term efficacy
for the treatment of neuropathic pain, back pain, osteoarthritis, cancer pain, and fibro-
myalgia (Cepeda et al. 2007; Deshpande et al. 2007; Eisenberg et al. 2006; Furlan et al.
2006; Martell et al. 2007; Noble et al. 2008). However, these trials have limited follow-up
periods (around 16 weeks) (Deshpande et al. 2007; Furlan et al. 2006; Noble et al. 2008)
and in the trials with longer follow-up periods, the lack of generalizability of the findings
has been identified as a serious shortcoming (Deshpande et al. 2007). Observational
healthcare databases provide an opportunity to assess their long term safety in a population
based setting.
In this research we explore the question of how opioid exposures can be identified in
observational healthcare databases through the use of standard vocabularies and classifi-
cation systems.
Although most observational healthcare databases capture individual patient drug
exposures, there is no single, standard drug coding scheme. In general, finding a com-
prehensive and accurate list of drug codes for these studies is cumbersome and time
consuming. Code sets can be inconsistent across investigators as it requires manual review
of code lists, often generated through a simple text search and unique to a specific database.
Code set development is susceptible to multiple forms of errors including the omission of
relevant codes and inadvertent code inclusion.
In U.S. based databases, commonly used coding schemes include the National Drug
Code (NDC) (National Drug Code Directory 2011), Generic Product Identifier (GPI)
(Master Drug Data Base v2.5 (MDDB) 2011) or Veterans Affairs National Drug File
(NDF) (National Formulary 2011) while outside the U.S. different coding schemes will be
found. In addition drug exposures are captured as procedural administrations and repre-
sented in adjacent coding schemes (i.e., Healthcare Common Procedure Coding System
(HCPCS) (HCPCS General Information 2011)).
Even after a single database and coding terminology are selected for study, analysis is
further complicated by the process for selecting the proper set of codes as most coding
schemes lack an obvious biologically or ingredient-based organizational structure. In these
cases a classification system may be selected and applied to the underlying coding scheme
in order to identify a particular class of drug. The National Library of Medicine provides
RxNorm (An Overview to RxNorm 2011) as a standardized nomenclature for clinical
drugs that provides classifications of branded products and generic ingredients. Addi-
tionally there are multiple classification systems available including the First DataBank
Enhanced Therapeutic Classification (ETC.) system (Enhanced Therapeutic Classification
System 2011), World Health Organization (WHO) Anatomical Therapeutic Chemical
(ATC) classification system (WHOCC-Structure and principles 2011), and Veterans
Affairs (VA) National Drug File Reference Terminology (NDF-RT) (National Drug File-
Reference Terminology (NDF-RT) 2011) and each varies in content and structure.
In an effort to address the challenge of multiple coding systems and terminologies, the
Observational Medical Outcomes Partnership (OMOP) (Stang et al. 2010) compiled
multiple standardized terminologies and classification systems into an interrelated
vocabulary. This vocabulary relies on existing standards and mappings, and leverages work
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within the Unified Medical Language System’s Metathesaurus (UMLS-Metathesaurus
2011). This study evaluates the use of the OMOP vocabulary in a network of disparate
observational databases and explores the ability of its multiple standardized terminologies
and classification systems to define an appropriate pool of codes for opioid exposure.
2 Materials and methods
Standard vocabularies, classification systems and their relationships were derived from the
OMOP’s Standard Terminologies [(OMOP Standard Terminologies 2011); this reference
contains the complete set of standard terminologies]. Based on the expertise of our research
team, oxycodone was used as a seed ingredient to define an opioid drug grouping in each
drug classification system. We identified the point at which oxycodone was categorized
within each hierarchy and selected the highest-level drug class that subsumed oxycodone
while still being inclusive of other opioid-related drugs. The classes identified through this
process were ‘Analgesic-Narcotic’ in ETC., ‘Opioids’ in ATC, and ‘Opioid Agonist’ in
NDF-RT. Iterative exploration of ingredients subsumed within these classes was used to
exclude other potential classes. Source codes were identified as all codes mapped to any
descendent concept within the identified drug class. The source codes identified from each
classification system were compared to identify overlap across the three systems. The
string terms for all opioid ingredients identified by the three systems (e.g. ‘oxycodone’,
‘hydrocodone’, ‘codeine’) were used in lexical searches amongst all NDC descriptions for
codes not previously classified as ‘opioids’ to identify any potentially unmapped source
codes. The prevalence of opioid exposure was estimated for each definition based on
occurrence of at least one coded record as either an 11 digit NDC code from a pharmacy
dispensing record or a HCPCS from a procedural administration.
While the focus of this paper is the exploration of classification system variation as it
relates to opioids additional high level analysis was performed to ensure this was not
simply an issue in one therapeutic category. The high level analysis was repeated for
NSAIDs, Antidiabetics and Antidepressants and we found the variation also occurs in these
other therapeutic areas. While we do not discuss these results further we have included the
results for review (see Table 3).
To ensure that there was no substantial impact of the addition or removal of pharma-
cologic agents over time additional data has been provided which stratify the prevalence
over time using each of the three individual classification systems (see Table 2).
Three observational healthcare databases were included in this study; the MarketScan
Commercial Claims and Encounters (CCAE), Medicare Supplemental (MDCR) databases,
MarketScan Medicaid (MDCD) database, and OptumInsight Clinformatics (OPTUM)
database.
The MarketScan Commercial Claims and Encounters Database consists of employer
and health plan sourced data for several million individuals containing medical and drug
data linked to outpatient prescription drug claims and person-level enrollment information.
Similar data are also available for the subset of employee retirees who have supplemental
Medicare coverage (MDCR) (David et al. 2008). The MarketScan Medicaid Database
captures similar data for Medicaid enrollees in several states (David et al. 2008). Results
from the CCAE and MDCR databases were combined as the patient records can be
continuous across the two databases (CCAEMDCR). The version of the CCAEMDCR
database used in this study contained data from 2000 to 2009. The version of the MDCD
database used in this study contained data from 2006 to 2008.
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The OptumInisght (OPTUM) Clinformatics database contains patient-level data inclu-
sive of administrative data, pharmacy claims data, physician and facility claims data, and
lab test results from enrollees in managed care plans administered by United Health Group
(i3 InVision Data Mart 2010). The version of the OPTUM database used in this study
contained data from 2005 to 2010.
While the observational healthcare databases used in this study are only available under
licenses from their respective organizations, the OMOP vocabulary is publically available
allowing further investigation of our results against other available data sources.
An opioid related literature review was conducted to assess the proportion of papers that
explicitly articulate the code set used or a description of the process used to develop the
code set.
3 Results
3.1 Composite code mappings
Basic information for each database was captured to provide a summary of the number of
prescription drug claim records and unique drug codes represented. We found that between
55.8 and 69.2 % of 11 digit NDC codes in the observational databases were successfully
mapped to the concepts represented in the OMOP standard vocabulary. The set of mapped
codes accounted for between 93.8 and 95.1 % of the total prescription drug claim records
found in the observational databases (see Table 1).
3.2 Classification systems
A substantial overlap between the opioid definitions based on the ATC, NDF-RT and ETC.
classification systems was found by comparing the 11 digit NDC codes they identified.
9,207 NDCs were captured by all of the 3 classification systems. (see Fig. 1). Each of the
drug classification systems also yielded NDCs that were not found by any of the other two
systems; 1,192 NDC codes were uniquely identified using NDF-RT, 1,898 codes were
uniquely identified using ETC., and 2 codes were uniquely identified using ATC (see
Table 3). The full set of NDC codes identified by all classification systems is provided in
Appendix 1 which is available upon request due to its large size.
The prevalence of opioid usage was estimated across each of the observational
healthcare database using the three classification systems. If ‘opioid’ were defined only by
Table 1 Composite code mappings across three observational healthcare databases
Observational healthcare databases
CCAEMDCR MDCD OPTUM
No. distinct drug codes (11 digit NDC) 133,117 47,605 67,031
No. drug records 2,605,047,390 133,879,982 691,892,761
No. mapped codes 74,288 32,977 42,439
No. records covered by mapping 2,479,374,599 126,094,396 649,029,503
% of codes mapped 55.8 69.3 63.3
% of records covered by mapping 95.2 94.2 93.8
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‘Opioids’ class in ATC, the observed prevalence in CCAEMDCR was 19.2 %. Defining
‘opioids’ using the ETC. ‘Narcotic analgesic’ class yielded a prevalence of 31.6 % while
defining ‘opioids’ as all products based on the ‘Opioid agonist’ mechanism of action in
NDF-RT produced a CCAEMDCR prevalence of 28.8 %. Using a composite set of 11 digit
NDCs based on all three classification systems produced a prevalence of 33.1 %. (see
Table 2).
3.3 Classification hierarchies
Table 3 highlights the vocabulary classification of opioid-related ingredients identified by
the three classification systems. NDF-RT has a classification based on mechanism of
action. In this study we used drugs classified as ‘Opioid agonists’, however several of the
qualifying drugs, such as buprenorphine are also classified as ‘opioid antagonists’.
Alfentanil and codeine were not classified as opioid agonists, but instead are represented
with the ‘opioid receptor interactions’ mechanism of action. The ATC classification system
contains a high-level class for ‘opioids’, which is further segregated by ‘natural opioid
alkaloids’ and various derivatives, including phenylpiperidine, benzomorphan, oripavine,
and morphinan. Alfentanil, remifentanil, and sufentanil are classified elsewhere under
‘Anesthetics, general’ as ‘opioid anesthetics’. Surprisingly, hydrocodone is not classified in
the ‘opioid’ class, but instead placed under the classes of cough suppressants (including
‘opium derivatives and expectorants’ and ‘opium alkaloids and derivatives) and other
analgesics under ‘anilides’. Within the ETC’s hierarchy, most active ingredients of interest
are subsumed within the class of ‘Narcotic analgesic’, which was further stratified by
combination ingredient. There is no concept for the term ‘opioid’ within the ETC. clas-
sification system. Notably, opium is classified elsewhere as an antidiarrheal and GI anti-
spasmodic combination, while remifentanil and sufentanil are classified as ‘generic
anesthetic adjuncts–narcotic’.
Fig. 1 Overlap in coverage of ‘opioid’ NDC drug codes by classification system
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4 Discussion
Standard drug vocabularies have utility in many applications. They provide a useful tool
for comparing the prevalence of drugs across disparate data sources, assist in the identi-
fication of drugs within a class, and can help define a comparator population based on
treatments for the same indication. Vocabularies can also help identify codes for exposures
that appear as drug administration procedures as well as all combination drugs that include
a specific active ingredient.
A relatively low percentage of all distinct drug codes found in the observational
healthcare databases can be mapped to the standard drug vocabularies used in this study
(55.8–69.2 %). The codes that do not map appear to be due to erroneous coding in the
source data, incomplete mappings, and limitations of the target vocabularies. Despite the
low percentage of distinct code mappings we found that a vast majority of data records
were successfully mapped to the used vocabularies (93.8–95.2 %). While further work can
potentially enhance the quality and completeness of code mappings, we believe that the
law of diminishing returns will quickly reduce the amount of additional information
captured through a more extensive mapping. The biggest benefit of applying drug clas-
sification standards would be in eliminating erroneous data by ensuring that all drug codes
match standard vocabularies.
It is clear through this opioid example that there is no superior classification system and
that there is substantial value in using multiple drug classification systems concurrently to
reduce the risk of under-ascertainment of exposure. For example, restricting to only the
Table 3 Identification of related 11 digit NDC codes by drug class and vocabulary






Opioid ATC Opioids 23 1,122 11,765 2
Opioid ETC. Analgesics–narcotic 20 1,808 19,106 333
Opioid NDFRT Opioid agonists 22 1,813 15,912 1,087
Opioid VA Opioid analgesics 24 1,750 17,113 450
NSAID ATC Antiinflam and antirheumatic
products, non-steroids
52 1,109 18,519 374
NSAID ETC. NSAID analgesics 23 970 18,160 –
NSAID NDFRT NSAID analgesics 23 970 18,160 –
NSAID VA Nonsalicylate NSAIDs,
antirheumatic
24 926 18,290 195
Antidiabetic ATC Drugs used in diabetes 53 483 7,475 47
Antidiabetic ETC. Oral antidiabetic agents 19 309 7,197 77
Antidiabetic NDFRT Insulin receptor agonists 42 445 7,114 14
Antidiabetic VA Oral hypoglycemic agents 18 273 6,965 –
Antidepressant ATC Antidepressants 47 665 17,542 246
Antidepressant ETC. Antidepressants 29 608 17,419 3




40 1,030 20,670 4,406
Antidepressant VA Antidepressants 29 604 17,114 –
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ATC system would lead to the exclusion of hydrocodone—one of the most commonly
prescribed opioids—as well as buprenorphine and methadone that, although used for the
treatment of opioid dependence, are also used for the treatment of pain. Restricting to only
the NDF-RT system would lead to the exclusion of tapentadol, a recently approved opioid.
Additionally restricting to only the NDF-RT system would lead to the exclusion of
alfentanil, but to the inclusion of other similar opioids with only intravenous formulations
such as sufentanil.
Each classification system simply reflects a different perspective for organizing clinical
concepts and the most value can be realized by leveraging multiple perspectives, which
would lead to a more complete representation. While ETC. had the highest coverage of the
opioid NDCs, the high level analysis of the three other therapeutic areas showed that no
single classification system consistently exhibited this capability.
In our opinion, inclusion of drug code sets and a description of the process used to
develop code sets in publications would provide a significant value for the healthcare
research community. This level of detail is generally lacking in current literature. A
literature search was performed to determine how often authors reported the complete set
of drug codes used in observational database studies. The intent of this review was to
illustrate the potential for variation while attempting to reproduce other study results. We
limited the search to studies published in English and used the Medical Subject Headings
terms: ‘‘epidemiologic studies’’, ‘‘case–control studies’’, ‘‘cohort studies’’, and ‘‘follow-up
studies’’ combined with ‘‘Analgesics, Opioids’’ and the key word: ‘‘database’’. Out of the
23 studies (Cepeda et al. 2010; Chen et al. 2010; Franklin et al. 2008; Gallagher et al. 2009;
Gasse et al. 2000; Goettsch et al. 2007; Gross et al. 2009; Iyer et al. 2010; Jick et al. 1998;
Kwong et al. 2010; Massey et al. 2005; Parente et al. 2004; Pradel et al. 2004; Sittl et al.
2005; Skurtveit et al. 2010; Skurtveit et al. 2008; Sullivan et al. 2010; Victor et al. 2009;
Voaklander et al. 2008; Von Korff et al. 2011; White et al. 2009; Ytterberg et al. 1998;
Zorowitz et al. 2005) we identified as observational studies using electronic medical record
or claims databases, only three reported the drug codes used. Notably, the authors of these
manuscripts were the same and the codes provided were identical. Understanding the
process used to develop code sets provides a way for researchers to understand the deci-
sions made in the framing of the research question and in turn, determine possible
implications for replication of the results.
Code sets can be very large making peer reviewed publications a less than ideal location
to present them, however, they could be made available as an online supplement. Perhaps a
public library of code sets with appropriate definitions could be made available through the
National Library of Medicine or some other curated source.
5 Limitations
This is a single study of a single drug class and more research of additional drug classes
would be required to further support our conclusions.
Even with shared code sets reproducing results could be challenging given the fact that
observational healthcare databases have non-standard versions, formats, update frequen-
cies and time frames across different organizations.
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